Food and Drug Administration (FDA) Research This is an RSS file. You can use it to subscribe to this data in your favourite RSS reader or to display this data on your own website or blog.

Formulating biopharmaceuticals using three-dimensional printing
J Pharm Pharm Sci. 2024 Mar 15;27:12797. doi: 10.3389/jpps.2024.12797. eCollection 2024.ABSTRACTAdditive manufacturing, commonly referred to as three-dimensional (3D) printing, has the potential to initiate a paradigm shift in the field of medicine and drug delivery. Ever since the advent of the first-ever United States Food and Drug Administration (US FDA)-approved 3D printed tablet, there has been an increased interest in the application of this technology in drug delivery and biomedical applications. 3D printing brings us one step closer to personalized medicine, hence rendering the "one size fits all" concept in drug d...
Source: J Pharm Pharm Sci - April 1, 2024 Category: Drugs & Pharmacology Authors: Alistair K C Chan Nehil Ranjitham Gopalakrishnan Yannick Leandre Traore Emmanuel A Ho Source Type: research

Formulating biopharmaceuticals using three-dimensional printing
J Pharm Pharm Sci. 2024 Mar 15;27:12797. doi: 10.3389/jpps.2024.12797. eCollection 2024.ABSTRACTAdditive manufacturing, commonly referred to as three-dimensional (3D) printing, has the potential to initiate a paradigm shift in the field of medicine and drug delivery. Ever since the advent of the first-ever United States Food and Drug Administration (US FDA)-approved 3D printed tablet, there has been an increased interest in the application of this technology in drug delivery and biomedical applications. 3D printing brings us one step closer to personalized medicine, hence rendering the "one size fits all" concept in drug d...
Source: Journal of Pharmacy and Pharmaceutical Sciences - April 1, 2024 Category: Drugs & Pharmacology Authors: Alistair K C Chan Nehil Ranjitham Gopalakrishnan Yannick Leandre Traore Emmanuel A Ho Source Type: research

CB ‐0821, a novel CC chemokine receptor 5 (CCR5) inhibitor with improved binding efficacy proposed as anti‐HIV candidate: Computational and in vitro approach
In this study, CB-0821, identified from the ChemBridge library, emerged as a promising CCR5 inhibitor. Molecular dynamics simulations indicate comparable dynamic properties for CB-0821 and MVC. In silico comparisons with other CCR5 inhibitors emphasize CB-0821's superior binding affinity, positioning it as a potential lead compound. Evaluations of the dissociation constant (Ki) and absorption, distribution, metabolism, and excretion predictions suggest CB-0821 as a well-tolerated drug. Furthermore, the dose-dependent inhibition of CCR5 by CB-0821 in Peripheral blood mononuclear cells (PBMCs) (ranging from 10 to 200 nM) d...
Source: Biotechnology and Applied Biochemistry - April 1, 2024 Category: Biochemistry Authors: Ashish Kumar Tags: ORIGINAL ARTICLE Source Type: research

High systemic inflammation as a novel cardiovascular risk factor and target for anti-cytokine therapy: comment regarding the triglyceride glucose index
AbstractIn the last century, there has been more than enough research that proved the association of high lipid and glucose levels with cardiovascular disease, thus establishing the current well-known traditional cardiovascular risk factors such as dyslipidemia, diabetes, and metabolic syndrome. Hence, these cardiovascular risk factors are target therapy for glucose and lipid-lowering agents to prevent adverse cardiovascular events. However, despite controlling the lipid and glucose levels, some studies demonstrated the subclinical atherosclerosis suggesting that these cardiovascular risk factors alone cannot account for t...
Source: The International Journal of Cardiovascular Imaging - April 1, 2024 Category: Radiology Source Type: research

Unraveling the Potential of Water-Free Cyclosporine in Dry Eye Disease
In this issue of JAMA Ophthalmology, Peng and associates scrutinize the efficacy of SHR8028 (CyclASol 0.1% [Novaliq GmbH]), a water-free cyclosporine ophthalmic solution, 0.1%, used in the treatment of aqueous-deficient dry eye disease. SHR8028 uses a novel water-free vehicle perfluorobutylpentane (F4H5). Peng and associates conducted a rigorous randomized, double-masked, and vehicle-controlled phase 3 clinical trial in China that meticulously evaluates this innovative solution. A study of comparable but larger scale, namely the ESSENCE-2 randomized clinical trial, was piloted in the United States and published in JAMA Oph...
Source: JAMA Ophthalmology - April 1, 2024 Category: Opthalmology Source Type: research

Cabozantinib Response in a Patient With NSCLC Harboring Both MET Exon 14 Skipping Mutation and Secondary RET Fusion: A Case Report
JTO Clin Res Rep. 2024 Feb 7;5(4):100647. doi: 10.1016/j.jtocrr.2024.100647. eCollection 2024 Apr.ABSTRACTMET exon 14 skipping mutation has emerged as a new oncogenic driver in NSCLC with available targeted therapies, including Food and Drug Administration-approved inhibitors capmatinib and tepotinib. Potential resistance mechanisms are beginning to be described and include several on-target and off-target mutations. Here, we report an emergent secondary RET fusion in a patient with a primary MET exon 14 skipping mutation that progressed on capmatinib after the initial response. Subsequently, this patient received both a R...
Source: Cell Research - March 29, 2024 Category: Cytology Authors: Carlos Torrado Jamie Feng Elizabeth Faour Natasha B Leighl Source Type: research

Cabozantinib Response in a Patient With NSCLC Harboring Both MET Exon 14 Skipping Mutation and Secondary RET Fusion: A Case Report
JTO Clin Res Rep. 2024 Feb 7;5(4):100647. doi: 10.1016/j.jtocrr.2024.100647. eCollection 2024 Apr.ABSTRACTMET exon 14 skipping mutation has emerged as a new oncogenic driver in NSCLC with available targeted therapies, including Food and Drug Administration-approved inhibitors capmatinib and tepotinib. Potential resistance mechanisms are beginning to be described and include several on-target and off-target mutations. Here, we report an emergent secondary RET fusion in a patient with a primary MET exon 14 skipping mutation that progressed on capmatinib after the initial response. Subsequently, this patient received both a R...
Source: Clinical Lung Cancer - March 29, 2024 Category: Cancer & Oncology Authors: Carlos Torrado Jamie Feng Elizabeth Faour Natasha B Leighl Source Type: research

Progression-free survival estimates are shaped by specific censoring rules: Implications for PFS as an endpoint in cancer randomized trials
Eur J Cancer. 2024 Mar 20;202:114022. doi: 10.1016/j.ejca.2024.114022. Online ahead of print.ABSTRACTKaplan-Meier analysis hinges on the assumption that patients who are censored- lost to follow-up, or only recently enrolled on the study- are no different, on average, than patients who are followed. As such, censoring these patients- omitting their future information and taking the average of those who were followed- should not dramatically change the overall estimate. Yet, in a recent clinical trial, two sets of censoring rules- one favored by trialists and one favored by the US Food and Drug Administration- were applied ...
Source: Cancer Control - March 28, 2024 Category: Cancer & Oncology Authors: Vadim Lesan Timoth ée Olivier Vinay Prasad Source Type: research

Therapeutic prospects of nectin-4 in cancer: applications and value
This article reviews the diagnostic potential, prognostic significance, and molecular role of Nectin-4 in tumors, with a focus on clinical trials in the field of Nectin-4-related tumor treatment and the development of new drugs targeting Nectin-4. (Source: Frontiers in Oncology)
Source: Frontiers in Oncology - March 28, 2024 Category: Cancer & Oncology Source Type: research

Updated Review of Treatment of Androgenetic Alopecia
Alopecia, a widespread issue affecting both genders, often manifests as androgenetic alopecia, although a thorough examination is needed to rule out other causes. This chapter focuses on the treatment of androgenetic alopecia. Finasteride and minoxidil, the Food and Drug Administration –approved treatments, offer stability and in some cases improvement in scalp coverage. Platelet-rich plasma exhibits positive results as an off-label alopecia therapy. For eligible individuals, hair transplantation proves effective, using healthy follicular units to restore hair-bearing areas. Mul tiple options allow for the tailoring of i...
Source: Facial Plastic Surgery Clinics of North America - March 28, 2024 Category: Cosmetic Surgery Authors: Roy Xiao, Linda N. Lee Source Type: research

Outcomes of non-small cell lung cancer patients with non-V600E BRAF mutations: a series of case reports and literature review
Non-small cell lung cancer (NSCLC) is the most prevalent form of lung cancer, accounting for approximately 85% of cases of lung cancer. The standard first-line therapy for patients without oncogenic driver metastatic NSCLC is anti PD-L1 immune checkpoint inhibition (ICI) with platinum-based chemotherapy. Approximately 4% of NSCLC patients harbor BRAF mutations; the V600E mutation is the most common. Non-V600 mutations is an heterogeneous population and account for approximately 50% of BRAF-mutated NSCLC. BRAF mutations are classified into 3 functional classes based on their kinase activity and their signaling mechanism. Th...
Source: Frontiers in Oncology - March 27, 2024 Category: Cancer & Oncology Source Type: research

Potential use of proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibition and prevention method in viral infection
Microb Cell Fact. 2024 Mar 25;23(1):90. doi: 10.1186/s12934-024-02355-8.ABSTRACTCellular lipid membranes serve as the primary barrier preventing viral infection of the host cell and provide viruses with a critical initial point of contact. Occasionally, viruses can utilize lipids as viral receptors. Viruses depend significantly on lipid rafts for infection at virtually every stage of their life cycle. The pivotal role that proprotein convertase subtilisin/kexin Type 9 (PCSK9) plays in cholesterol homeostasis and atherosclerosis, primarily by post-transcriptionally regulating hepatic low-density lipoprotein receptor (LDLR) ...
Source: Atherosclerosis - March 26, 2024 Category: Cardiology Authors: Khursheed Muzammil Mohammad Hosseini Hooshiar Shirin Varmazyar Thabit Moath Omar Manal Morad Karim Sadeq Aadi Shaylan Kalavi Saman Yasamineh Source Type: research

Regulatory Issues of Platform Trials: Learnings from EU-PEARL
Clin Pharmacol Ther. 2024 Mar 26. doi: 10.1002/cpt.3244. Online ahead of print.ABSTRACTAlthough platform trials have many benefits, the complexity of these designs may result not only in increased methodological but also regulatory and ethical challenges. These aspects were addressed as part of the IMI project EU Patient-Centric Clinical Trial Platforms (EU-PEARL). We reviewed the available guidelines on platform trials in the European Union and the United States. This is supported and complemented by feedback received from regulatory interactions with the European Medicines Agency and the US Food and Drug Administration. ...
Source: Clinical Pharmacology and Therapeutics - March 26, 2024 Category: Drugs & Pharmacology Authors: Quynh Lan Nguyen Katharina Hees Sabina Hernandez Penna Franz K önig Martin Posch Marta Bofill Roig Elias Laurin Meyer Michaela Maria Freitag Tom Parke Maximilian Otte Hans-Peter Dauben Tobias Mielke Cecile Spiertz Peter Mesenbrink Madhavi Gidh-Jain Suzan Source Type: research